Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

TB-500 Dosing and Reconstitution

TB-500 Dosing and Reconstitution Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption Table of Contents 1. Dosing framing for TB-500 research 2. Published dose ranges 3. Reconstitution protocol 4

By Recovery & Performance Peptides Editorial Team

TB-500 Dosing and Reconstitution

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

1. Dosing framing for TB-500 research

2. Published dose ranges

3. Reconstitution protocol

4. Injection routes

5. Frequency — weekly vs twice-weekly

6. Duration by study type

7. Storage and aliquoting

8. Dose selection by research model

9. Comparison to BPC-157 protocols

10. Combination protocols

11. UK procurement and quality

12. Frequently asked questions

13. References

1. Dosing framing for TB-500 research

TB-500 (synthetic active-region analogue of thymosin beta-4) is an investigational peptide for UK laboratory research only. This guide summarises the published rodent protocol conventions to support UK research scientists designing in vitro, ex vivo, or licensed animal studies.

2. Published dose ranges

TB-500 rodent doses in the published literature commonly include:

150 µg/kg: used in some mouse studies, particularly cardiac research

2 mg per animal (absolute dose): typical low-end of absolute-dose protocols

5 mg per animal: common mid-range

10 mg per animal: common upper-range

Note the convention difference: some published protocols use per-kg dosing (typical in rigorous pharmacological studies), others use absolute per-animal dosing (common in tissue-repair protocols). Scientists should verify which convention applies to any specific protocol reference.

3. Reconstitution protocol

TB-500 is supplied lyophilised. Reconstitution with bacteriostatic water for injection (preserved with 0.9% benzyl alcohol) is standard — this supports multi-week storage at 2-8°C.

Reconstitution math for a 5 mg vial:

1 ml diluent → 5 mg/ml (high concentration)

2 ml diluent → 2.5 mg/ml (common research reference)

5 ml diluent → 1 mg/ml (for small-volume aliquots)

Reconstitution procedure:

Swab vial rubber seal with alcohol wipe.

Inject bacteriostatic water slowly down the inner wall of the vial.

Swirl gently (do not shake) until fully dissolved.

Inspect clarity — should be clear with no particulates.

4. Injection routes

Route of administration in published TB-500 rodent research:

IM (intramuscular): most common; sustained release profile

SC (subcutaneous): widely used; slower absorption

IP (intraperitoneal): systemic rapid delivery

IV (intravenous): in some cardiac acute studies

Intracardiac / local: in specific cardiac research protocols

Unlike BPC-157, TB-500 does not have strong oral-activity evidence — injection routes are the standard.

5. Frequency — weekly vs twice-weekly

TB-500 is commonly dosed less frequently than BPC-157:

Weekly — most common in tissue-repair protocols

Twice-weekly — used in more acute research models or when higher sustained exposure is the design goal

Daily — less common; when used, typically at lower per-dose amounts

The less-frequent dosing reflects TB-500’s apparently longer half-life relative to BPC-157. However, rigorous comparative PK data between the two peptides are limited.

6. Duration by study type

Typical protocol durations:

Acute injury (muscle, tendon, cardiac): 2-4 weeks

Subacute research applications studies: 4-6 weeks

Chronic remodelling or long-term studies: 6-12 weeks

Research safety studies: 12+ weeks in extended protocols

7. Storage and aliquoting

Storage reference:

Lyophilised TB-500 (unopened): 2-8°C for 2 years; −20°C for extended-storage.

Reconstituted in bacteriostatic water: 2-8°C protected from light; approximately 28 days stable (verify against COA).

Reconstituted in sterile water: use same day; otherwise aliquot and freeze at −20°C.

Aliquoted for freezer: single-use microtube aliquots at −20°C (−80°C preferred for long-term).

Pragmatic workflow for a 5 mg vial supporting a 4-week study:

Reconstitute in 2 ml bacteriostatic water → 2.5 mg/ml.

Store at 2-8°C, protected from light.

Draw weekly doses sterilely.

Discard remaining peptide after 28 days or if any sign of degradation.

8. Dose selection by research model

Representative doses by endpoint:

Cardiac post-MI (mouse): 150 µg/kg IP, often single or repeated dosing in acute protocols

Cardiac post-MI (rat): higher absolute doses, scaled by species weight

Skeletal muscle injury (rat): 2-10 mg per animal, IM or SC, weekly for 2-6 weeks

Dermal wound healing: topical or systemic dosing depending on design

Corneal wound healing: topical administration in eye drops (specialised formulation)

CNS / stroke models: typically IP or SC systemic administration

9. Comparison to BPC-157 protocols

Side-by-side:

BPC-157: 10 µg/kg daily, IP or IM, for 14-30 days

TB-500: 2-10 mg per animal weekly or twice-weekly, IM or SC, for 2-6 weeks

Both peptides reconstitute in bacteriostatic water and use similar storage protocols. The main differences are dose-per-administration amount, dosing frequency, and route emphasis (BPC-157 supports oral activity; TB-500 does not strongly).

10. Combination protocols

Some research protocols combine TB-500 and BPC-157, reasoning that the complementary mechanisms (actin cytoskeleton regulation + VEGFR2/FAK angiogenesis and fibroblast migration) should compound. Evidence for synergistic effect in rigorous factorial designs is limited. Combination protocols typically use each peptide at its standard dose and frequency, maintained across the combination arm.

See our BPC-157 vs TB-500 Comparison for the mechanism and protocol contrast.

11. UK procurement and quality

UK research-grade TB-500 procurement requirements:

≥ 98% HPLC (≥ 99% emerging 2026 standard)

Sequence explicitly disclosed on COA (supplier-to-supplier variation)

Identity MS confirmation per batch

Batch-specific Certificate of Analysis

Lyophilised format, UK cold-chain dispatch

Endotoxin testing for cell/animal work batches

See our Research-Grade Peptides Guide for standards detail and UK Research Peptide Buying Guide for sourcing due diligence.

12. Frequently asked questions

What is the typical TB-500 dose in rodent studies?

Typical doses span 2-10 mg per animal absolute (varying by study convention), with weekly or twice-weekly administration over 2-6 weeks. Cardiac studies often use per-kg dosing (e.g., 150 µg/kg).

How should TB-500 be reconstituted?

Add bacteriostatic water to the vial slowly down the inner wall, swirl gently. A 5 mg vial in 2 ml bacteriostatic water produces 2.5 mg/ml — the common research concentration.

How long is reconstituted TB-500 stable?

Approximately 28 days at 2-8°C in bacteriostatic water, protected from light. Verify against the batch-specific COA.

Weekly or twice-weekly dosing — which is better?

Most published tissue-repair protocols use weekly administration. Twice-weekly is an option for more acute models or when higher sustained exposure is the design goal. The choice should be protocol-specific.

Is TB-500 effective orally?

Unlike BPC-157, TB-500 does not have strong evidence for retained oral activity. Injection routes are the standard research convention.

What’s the difference in dosing frequency between TB-500 and BPC-157?

BPC-157 is typically dosed daily despite its short half-life (PK-PD disconnect). TB-500 is typically dosed weekly or twice-weekly, reflecting a longer apparent biological half-life.

Can TB-500 be combined with BPC-157?

Combination protocols exist but rigorous evidence for synergistic vs additive effect is limited. Factorial-design protocols (vehicle / TB-500 / BPC-157 / combination) are needed to resolve the question.

13. References

Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012;12(1):37-51.

Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-472.

Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature 2007;445(7124):177-182.

Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 2010;24(7):2144-2151.

Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999;113(3):364-368.

Philp D, Goldstein AL, Kleinman HK. Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev 2004;125(2):113-115.

Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002;74(2):293-299.

Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci 2010;1194:179-189.

Morris DC, Chopp M, Zhang L, Zhang ZG. Thymosin beta4: a candidate for treatment of stroke? Ann N Y Acad Sci 2010;1194:112-117.

Bollini S, Riley PR, Smart N. Thymosin β4: multiple functions in protection, repair and regeneration of the mammalian heart. Expert Opin Biol Ther 2015;15 Suppl 1:S163-174.

UK Research Cluster Hubs

TB-500 UK Research Guide

BPC-157 UK Research Guide

GLP-1 Peptides Complete Research Reference

Retatrutide UK Research Guide

Tirzepatide UK Research Guide

Research-Grade Peptides Standards Guide

UK Research Peptide Buying Guide

Disclaimer: TB-500 is an investigational peptide not approved for human use in the UK, EU or US. All products supplied by Peptides Lab UK are for licensed in vitro and ex vivo laboratory research purposes only. Not for human consumption, veterinary use, or any therapeutic application.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to reconstitute TB-500 (Ac-LKKTETQ)

The materials you'll need and step-by-step instructions for safely mixing TB-500 (Ac-LKKTETQ) with bacteriostatic water. Materials needed Your TB-500 (Ac-LKKTETQ) vial (lyophilized) Alcohol swabs Bacteriostatic sterile water 3 mL syringes (Luer Lock tip) 25G or 27G needles (Luer Lock). Other gauges may also be acceptable. Sharps container (optional) Remove the caps Sanitize the rubber stoppers Attach the needle Draw the bac water Pull back on the plunger to draw your desired volume of bacteriostatic water. If you overfill, just push the excess back in until you reach the right marker on the syringe. Insert the needle into the TB-500 (Ac-LKKTETQ) vial With the bac water in your syringe, insert the needle into the TB-500 (Ac-LKKTETQ) vial at a slight angle to avoid pressure buildup. Release the water gently Let the water run gently down the side of the vial. Don't inject it forcefully. Swirl to dissolve Avoid shaking. Gently swirl, flip, and roll the vial to dissolve the powder. Check for full dissolution Cap, dispose, and store
DOSAGE SOURCE

TB-500 Dosing Table

Match your vial size below — reconstitution and dose math update automatically. 500 mcg 20 units 0.2 mL Daily SubQStandard 750 mcg 30 units 0.3 mL Daily SubQ 2 mg 80 units 0.8 mL 2x/week SubQLoading dose (week 1-4) Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before injecting. Round half-units to the nearest visible mark. 10 units 0.1 mL 1 mg 40 units 0.4 mL 2x/week SubQLoading Running TB-500? Share your protocol Anonymous · about 20 seconds · see how yours compares
02

Question drills

Open a question for its connected answer.

01What If My Research Model Requires Rapid Angiogenesis Without Structural Protein Emphasis?+

Use TB-500 as a standalone compound. The peptide's primary strength lies in VEGF upregulation and endothelial cell migration. Both critical for new blood vessel formation. Research models involving ischemic tissue recovery, wound healing with poor vascular supply, or pure angiogenesis studies benefit from TB-500's targeted mechanism without the additional growth hormone receptor activation that BPC-157 contributes. A 2019 study in Regenerative Medicine demonstrated that Tβ4 administration alone increased capillary density by 85% in ischemic limb models within 14 days, suggesting the compound's angiogenic effects are sufficient for vascular-focused research without combination protocols.

SOURCE / realpeptides.co ↗
02What If My Meniscus Tear Was Diagnosed as 'Inoperable' Due to Location?+

Start TB-500 protocol at standard dosing (2–2.5mg twice weekly) regardless of surgical candidacy. The peptide's cell migration effects work in poorly vascularised zones where surgical repair fails. Combine with controlled loading: maintain range-of-motion work and low-impact strengthening while avoiding deep flexion past 90 degrees for the first 8 weeks. Tears in the inner avascular zone won't 'heal' in the sense of returning to pre-injury MRI appearance, but tissue remodelling can reduce pain and improve mechanical function enough to avoid or delay total meniscectomy.

SOURCE / realpeptides.co ↗
03What If You're Considering TB-500 for a Non-Healing Surgical Wound?+

A non-healing wound requires diagnostic evaluation first—infection, ischemia, foreign body retention, or underlying systemic factors (diabetes, immunosuppression, malnutrition) must be ruled out before attributing delayed healing to a peptide deficiency. TB-500 does not address bacterial colonization, inadequate debridement, or compromised perfusion. If standard wound care interventions (negative pressure therapy, hyperbaric oxygen, vascular optimization) have failed, enrollment in a formal research protocol may be appropriate—but purchasing research-grade peptides without medical oversight is not equivalent to evidence-based wound management.

SOURCE / realpeptides.co ↗
04What If I Missed a Scheduled Dose and the Reconstituted Vial Is Now Beyond 28 Days?+

Discard the vial and reconstitute a fresh one. The 28-day window for bacteriostatic water-reconstituted peptides isn't arbitrary. It reflects the point at which bacterial contamination becomes statistically probable even with preserved solution. Using peptides beyond this window introduces infection risk that far exceeds any potential benefit. If you frequently have leftover peptide at the 28-day mark, consider purchasing smaller vials or aliquoting reconstituted solution into single-dose syringes and freezing them for later use.

SOURCE / realpeptides.co ↗
05What If You Need to Combine TB-500 With Other Growth Factors?+

TB-500 synergizes with VEGF, FGF-2, and PDGF through non-overlapping mechanisms. Combination treatment routinely produces additive or super-additive effects. Apply growth factors at standard concentrations (VEGF 20–50 ng/mL, FGF-2 10 ng/mL) and TB-500 at 200 ng/mL simultaneously; the growth factors provide directional cues (chemotaxis) while TB-500 enhances cellular capacity to respond (cytoskeletal readiness). Avoid combining with other actin-binding peptides (phalloidin, cytochalasin analogs) that compete for the same binding sites and create unpredictable cytoskeletal effects.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Why High Purity is Non-Negotiable in TB-500 Cardiac Repair Research

When exploring something as sensitive and critical as TB-500 cardiac repair, the purity and consistency of the research materials are paramount. Contaminants or inconsistent peptide sequencing can lead to skewed results, misinterpretations, and ultimately, wasted time and resources. Our team at Real Peptides understands this implicitly. It’s what drives our entire philosophy. We specialize in small-batch synthesis with exact amino-acid sequencing, guaranteeing the purity and consistency our researchers rely on. This commitment extends across our full range, including specialized compounds like TB-500 (thymosin Beta-4) for regenerative studies. You can't compromise on quality when you're pushing the boundaries of science. Honestly, though, it's the bedrock of credible research. We can't stress this enough when it comes to advancing TB-500 cardiac repair studies. While other solutions in the market might offer varied purity levels, we prioritize precision. This approach (which we've refined over years) delivers real results in the lab, helping scientists confidently pursue complex research questions without worrying about the integrity of their peptides. It’s about empowering breakthroughs, not just selling products.

RESEARCH

What Are the Key Research Applications for TB-500?

Now, this is where the rubber meets the road. The applications being explored for TB-500 are quite diverse, reflecting its broad cellular influence. We often discuss these with our clients seeking high-purity research materials, emphasizing the precision and consistency that Real Peptides provides for compounds like TB-500 (thymosin Beta-4). Here’s a breakdown of some of the most prominent research avenues: Tissue Repair and Regeneration: This is perhaps the most widely recognized area. Studies are investigating its role in accelerating wound healing, repairing muscle damage, and enhancing recovery from various injuries. It's not just about speed, but also about the quality of the regenerated tissue. Cardiac Health: Researchers are exploring TB-500's potential in promoting cardiac tissue repair following injury, such as myocardial infarction. Its ability to stimulate angiogenesis and reduce scar tissue formation is of particular interest. Neurological Studies: There's growing research into TB-500's neuroprotective effects and its potential to aid in recovery from brain injury or neurodegenerative conditions. It’s thought to support neuronal survival and reduce inflammation in the central nervous system. Ocular Health: Given its regenerative capabilities, TB-500 is being studied for its role in corneal repair and other eye conditions, where rapid, effective tissue healing is crucial. Anti-Inflammatory Research: As mentioned, its ability to modulate inflammation makes it a candidate for studies into conditions where chronic inflammatory processes are at play. This aspect is frequently highlighted in any TB-500 FAQ. We can't stress this enough: the breadth of its potential applications means researchers need exceptionally reliable materials, which is precisely what we synthesize here at Real Peptides. This approach (which we've refined over years) delivers real results in terms of research integrity.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles